ArticleAmerican journal of hematology2016

Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.

Talha Badar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.